Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Add" for 药明康德 (WuXi AppTec) [6][53]. Core Insights - The report highlights the recent approval of new drugs, including 埃诺格鲁肽注射液 (Energulutide Injection), which is the first of its kind approved for adult type 2 diabetes patients [16]. - The report emphasizes the importance of the recent policies from the National Medical Security Administration aimed at enhancing the medical insurance landscape, which is expected to improve service levels and create development opportunities in the industry [14]. - The report notes significant growth in product revenues for companies like 信达生物 (Innovent Biologics) and 康方生物 (CanSino Biologics), indicating a positive trend in the sector [31][32]. Industry News - The National Medical Security Administration issued a notice to accelerate the cultivation and application of new scenarios in the medical insurance field, which is expected to enhance service levels and create industry development opportunities [14]. - The Ministry of Industry and Information Technology, along with seven other departments, released a plan for the high-quality development of the traditional Chinese medicine industry from 2026 to 2030, aiming to strengthen the entire industry chain [15]. - The report mentions that in 2025, the employee medical insurance personal account had a total of 4.64 billion person-times, with a total amount of 68.77 billion yuan [15]. Company Announcements - 信达生物 (Innovent Biologics) reported a strong revenue growth of approximately 45% year-on-year for 2025, with a significant increase in Q4 revenue due to new drugs being included in the national medical insurance directory [31]. - 康方生物 (CanSino Biologics) granted exclusive commercialization rights for 伊喜宁® (Evinacumab) to 济川药业 (Jichuan Pharmaceutical), receiving an upfront payment of 80 million yuan [32]. - 恒瑞医药 (Hengrui Medicine) has had several drug applications accepted by the FDA and NMPA, indicating ongoing progress in its product pipeline [33]. Market Review - The report notes a decline in major indices, with the SW Pharmaceutical and Biological sector down by 0.97% during the week of January 30 to February 5, 2026 [45]. - The overall industry P/E ratio as of February 5, 2026, was reported at 51.01 times, with a valuation premium of 261% relative to the CSI 300 index [47]. Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring companies involved in small nucleic acids and AI applications [53].

Group 1 - The core point of the news is that Kangfang Biologics has signed an exclusive commercialization rights agreement with Jichuan Pharmaceutical, granting Jichuan the rights to market and sell the drug Yixinning® (Inusimab Injection) in mainland China [1] - Kangfang Biologics will receive a total of RMB 80 million (including tax) as an upfront licensing fee and up to RMB 10 million (including tax) in milestone payments from Jichuan Pharmaceutical [1] - Jichuan Pharmaceutical will be responsible for the commercialization and sales of Yixinning® in the authorized market [1] Group 2 - Yixinning® is an innovative PCSK9 monoclonal antibody developed by the company, approved for market in September 2024 for treating primary hypercholesterolemia and mixed dyslipidemia [2] - The drug has been included in the latest National Medical Insurance Directory and is highly recommended in the 2025 edition of expert consensus on managing cardiovascular risks related to blood lipids [2] - Yixinning® works by specifically binding to PCSK9 and blocking its interaction with LDL-R, thereby enhancing the clearance of LDL-C from plasma, which has shown significant efficacy in reducing cholesterol levels and lowering the risk of heart attacks and strokes [2]

Core Insights - 康方生物 has signed an exclusive commercialization rights agreement with 济川药业 for its self-developed drug 伊喜宁® (Inusimab injection) in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - 康方生物 will receive a total of RMB 80 million (including tax) as an upfront licensing fee and up to RMB 10 million (including tax) in milestone payments from 济川药业, which will handle the commercialization and sales of 伊喜宁® in the authorized market [1] Group 1 - 伊喜宁® is an innovative PCSK9 monoclonal antibody developed by 康方生物, approved for treatment of primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) and high cholesterol in patients with atherosclerotic cardiovascular disease [2] - The drug has been included in the latest National Medical Insurance Directory and is highly recommended in the 2025 edition of expert consensus on managing cardiovascular risk related to blood lipids [2] - 伊喜宁® works by specifically binding to PCSK9 and blocking its interaction with LDL-R, thereby restoring LDL-R expression levels to enhance the clearance of LDL-C from plasma [2] Group 2 - Previous studies indicate that PCSK9 monoclonal antibody treatment significantly reduces cholesterol levels in patients already on statin therapy, lowering the risk of heart attacks and strokes [2] - Phase III clinical trials have shown that 伊喜宁® demonstrates excellent clinical efficacy across various risk stratifications, providing a new option for the clinical treatment of hypercholesterolemia and long-term control of cardiovascular risk [2]

Core Insights - 康方生物 has signed an exclusive commercialization rights agreement with 济川药业 for its self-developed drug 伊喜宁® (Inusimab injection) in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - 康方生物 will receive a total of RMB 80 million (including tax) as an upfront licensing fee and up to RMB 10 million (including tax) in milestone payments from 济川药业, which will handle the commercialization and sales of 伊喜宁® [1] Group 1 - 伊喜宁® is an innovative PCSK9 monoclonal antibody developed by 康方生物, approved for treatment of primary hypercholesterolemia and mixed dyslipidemia, including heterozygous familial hypercholesterolemia (HeFH) and high cholesterol patients with atherosclerotic cardiovascular disease [2] - The drug has been included in the latest National Medical Insurance Directory and is highly recommended in the 2025 edition of expert consensus on managing cardiovascular risk related to blood lipids [2] - 伊喜宁® works by specifically binding to PCSK9 and blocking its interaction with LDL-R, thereby restoring LDL-R expression levels to enhance the clearance of LDL-C from plasma [2] Group 2 - Previous studies indicate that PCSK9 monoclonal antibody treatment significantly reduces cholesterol levels in patients already on statin therapy, lowering the risk of heart attacks and strokes [2] - Phase III clinical trials have shown that 伊喜宁® demonstrates excellent clinical efficacy across various risk stratifications, providing a new option for the clinical treatment of hypercholesterolemia and long-term control of cardiovascular risk [2]

Core Viewpoint - Kangfang Biopharma has signed an exclusive commercialization rights agreement with Jichuan Pharmaceutical, granting Jichuan the exclusive rights to commercialize the drug Yixinning (Inusimab Injection) in mainland China, excluding Hong Kong, Macau, and Taiwan [1] Group 1: Agreement Details - The agreement involves Kangfang Biopharma's indirect wholly-owned subsidiary, Zhongshan Kangfang Biopharma Co., Ltd., and Jichuan Pharmaceutical's subsidiaries [1] - Kangfang Biopharma will receive a total of RMB 80 million (including tax) as a licensing fee from Jichuan Pharmaceutical, along with potential milestone payments of up to RMB 10 million (including tax) [1] - Jichuan Pharmaceutical will be responsible for the commercialization and sales of Yixinning in the authorized market [1]